A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

• Status: Completed
• Trial end date: 2019-03-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Lispro; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months

• Have a body mass index of 18.5 to 37 kilogram per meter squared

• Have a hemoglobin A1c level ≥6.0% and ≤9.0%

Exclusion Criteria:

• Have known allergies or history of hypersensitivity to insulin lispro

• Have had an episode of severe hypoglycemia within the past 6 months

• Have had more than 1 episode of diabetic ketoacidosis in the past 6 months